Syra Health Corp-A 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to______. Commission File Number 001-41822 SYRA HEALTH CORP.(Exact Name of Registrant as Specified in Its Charter) 85-4027995 1119 Keystone Way N. #201Carmel, IN 46032(Address of Principal Executive Offices) Registrant’s telephone number, including area code:(463) 345-8950 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredOTC QB SYRA Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☐No☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act.: Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares of the registrant’s Class A Common Stock outstanding as of May 8, 2026, was 11,339,169. PageNo.PART I. FINANCIAL INFORMATIONItem 1.Financial StatementsF-1Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025F-1Statements of Operations for the Three Months ended March 31, 2026, and 2025 (Unaudited)F-2Statements of Changes in Stockholders’ Equity for the Three Months ended March 31, 2026, and 2025 (Unaudited)F-3Statements of Cash Flows for the Three Months ended March 31, 2026, and 2025 (Unaudited)F-4Notes to the Financial Statements (Unaudited)F-5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations4Item 3.Quantitative and Qualitative Disclosures About Market Risk11Item 4.Controls and Procedures11PART II. OTHER INFORMATION12Item 1.Legal Proceedings12Item 1A.Risk Factors12Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities12Item 3.Defaults Upon Senior Securities12Item 5.Other Information12Item 6.Exhibits13Signatures142 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions ofSection 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934,as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,”“expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these termsor other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates andprojections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. Wemay not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or eventscould differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and ourforward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertaintiesinherent in our statements regarding: ●our projected financial position and estimated cash burn rate;●our estimates regarding expenses, future revenues and capital requirements;●our ability to continue as a going concern;●our need to raise substantial additional capital to fund our operations;●our ability to compete in the healthcare industry;●the timing, cost and success or failure of new product and service introductions, development and product upgrade releases;●competitive pressures including offerings and pricing;●our abilit